Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-09-30FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (VistaPharm, LLC)
FDA approved a supplemental application for a generic methadone hydrochloride product from VistaPharm, LLC. The drug is used for opioid use …
-
FDA approval · 2016-09-30FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Aurolife Pharma, LLC)
FDA approved a supplemental application for methadone hydrochloride from Aurolife Pharma, LLC, making a generic version of the drug availabl…
-
FDA approval · 2016-09-30FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Epic Pharma, LLC)
FDA approved a supplemental application for methadone hydrochloride from Epic Pharma, LLC.
-
FDA approval · 2016-09-30FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for a generic methadone hydrochloride product from Ascend Laboratories, LLC.
-
CLINICAL_TRIALS research · 2016-09-30Clinical Trial Update: Monitoring Patterns of Prescribing to Identify Changes in Access to ER/LA Opioid Analgesics
A clinical trial update describes monitoring prescribing patterns to assess changes in access to extended-release/long-acting opioid analges…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-09-30Clinical Trial Update: Evaluation of Changes in Prescribing Behavior of ER/LA Opioid Prescribers
Clinical trial update evaluating changes in prescribing behavior of extended-release/long-acting opioid prescribers. The current status of t…
-
CLINICAL_TRIALS research · 2016-09-29Clinical Trial Update: Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients
This completed clinical trial update compares the COMT Val158Met polymorphism between patients treated with COM-ON and those treated with ME…
-
FDA approval · 2016-09-19FDA Approved: BUPRENORPHINE AND NALOXONE — Original Application (Lannett Company, Inc.)
FDA approved a generic buprenorphine and naloxone product from Lannett Company (ANDA205022) under an original application, for the treatment…
-
CLINICAL_TRIALS research · 2016-09-13Clinical Trial Update: ER/LA Opioid Analgesics - Surveillance Monitoring of State Medical Examiner Databases
This clinical trial update covers ongoing surveillance monitoring of state medical examiner databases for safety monitoring of ER/LA opioid …
-
CLINICAL_TRIALS research · 2016-09-12Clinical Trial Update: Probuphine Innovations for Clinical Effectiveness (PRINCE) [NA]
Clinical trial update for Probuphine (buprenorphine implant) related to opioid use disorder, with the study status listed as UNKNOWN.
-
CLINICAL_TRIALS research · 2016-09-09Clinical Trial Update: Substance Dependence Satisfaction With Care and Quality Of Life
This clinical trial update concerns a study involving opioid use disorder and alcoholism, focusing on satisfaction with care and quality of …
-
CLINICAL_TRIALS trial_result · 2016-09-08Clinical Trial Update: Conflict Between Maternal Autonomy and Child Health in Substance-use
This completed clinical trial update examines the balance between maternal autonomy and neonatal health in the setting of substance use duri…
-
CLINICAL_TRIALS research · 2016-08-25Clinical Trial Update: Surveillance Monitoring of Opioid Abuse in Poison and Drug Treatment Centers
This clinical trial update describes surveillance monitoring of opioid abuse conducted in poison and drug treatment centers under the ER/LA …
-
CLINICAL_TRIALS trial_result · 2016-08-17Clinical Trial Update: Efficacy of Drug and Risk Counseling Among Methadone Patients in Jakarta, Indonesia [Phase 2]
Phase 2 trial evaluating the efficacy of an unspecified drug plus risk counseling in methadone-maintained patients in Jakarta, with outcomes…
-
CLINICAL_TRIALS research · 2016-08-10Clinical Trial Update: A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects [Phase 3]
A Phase 3 clinical trial update evaluating withdrawal effects after dosing oxycodone/naltrexone in individuals maintained on methadone.
-
FDA approval · 2016-08-05FDA Approved: BUPRENORPHINE AND NALOXONE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic buprenorphine and naloxone product under ANDA 201633.
-
CLINICAL_TRIALS trial_result · 2016-07-11Clinical Trial Update: Buprenorphine Maintenance Protocol - 1 [Phase 3]
Phase 3 trial of a buprenorphine maintenance protocol for opioid use disorder has completed.
-
CLINICAL_TRIALS trial_result · 2016-07-11Clinical Trial Update: Influence of Dexmedetomidine and Lidocaine on Opioid Consumption in Laparoscopic Intestine Resection [Phase 4]
Phase 4 trial update assessing whether dexmedetomidine and lidocaine reduce postoperative opioid consumption in patients undergoing laparosc…
-
CLINICAL_TRIALS trial_result · 2016-07-11Clinical Trial Update: Multicenter Clinical Trial of Buprenorphine - 3 [Phase 3]
Phase 3 clinical trial of buprenorphine for opioid use disorder has completed.
-
FDA approval · 2016-07-07FDA Approved: BUPRENORPHINE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for buprenorphine (generic) filed by Hikma Pharmaceuticals USA Inc.; this covers an update to the ap…
-
FDA approval · 2016-07-07FDA Approved: BUPRENORPHINE HYDROCHLORIDE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
FDA approved a supplemental application for buprenorphine hydrochloride (generic) from PAI Holdings, under ANDA 090622.
-
FDA approval · 2016-07-07FDA Approved: BUPRENORPHINE HCL AND NALOXONE HCL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals' supplemental application for buprenorphine HCl and naloxone HCl (buprenorphine and naloxone). This acti…
-
FDA approval · 2016-07-07FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
FDA approved a supplemental application for buprenorphine and naloxone from PAI Holdings (PAI Pharma), marking an additional approval for th…
-
FDA approval · 2016-07-07FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)
FDA approved a supplemental application for ZUBSOLV (buprenorphine hydrochloride and naloxone hydrochloride) by Orexo US, Inc., updating its…
-
FDA approval · 2016-07-07FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves a supplemental application for buprenorphine hydrochloride and naloxone hydrochloride dihydrate from Hikma Pharmaceuticals USA …